Jefferies cuts Merck sales forecast for remigromig after trial concerns
What happened
Jefferies cut its peak sales forecast for Merck's experimental eye treatment remigromig by 60% after detailed trial results raised concerns about its efficacy and safety compared with Lucentis. The drug met the statistical threshold for non-inferiority against Lucentis, but showed smaller numerical improvements in patients’ vision. Jefferies lowered its risk-adjusted peak sales estimate to $300 million.
Why it matters
The reduction in the sales forecast directly impacts Merck's revenue projections for the drug. The trial results indicated that remigromig delivered smaller improvements in vision and retinal thickness than the established treatment, Lucentis.
Who's involved
- MerckPublic company whose experimental eye treatment remigromig was evaluated in clinical trials
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MerckSpeculative
Merck could see its revenue projections decrease due to the cut in the drug's sales forecast.